Compound: Valganciclovir
SMILES: O=c1nc([nH]c2c1ncn2COC(COC(=O)[C@@H](N)C(C)C)CO)N
InChIKey: WPVFJKSGQUFQAP-GKAPJAKFSA-N
Synonyms: Valganciclovir, 175865-60-8, GCU97FKN3R, L-Valine, 2-((2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)methoxy)-3-hydroxypropyl ester, DTXSID8048288, CHEBI:63635, L-Valine, 2-[(2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)methoxy]-3-hydroxypropyl ester, 2-[(2-amino-6-oxo-6,9-dihydro-3H-purin-9-yl)methoxy]-3-hydroxypropyl (2S)-2-amino-3-methylbutanoate, valganciclovirum, 2-((2-amino-6-oxo-6,9-dihydro-3H-purin-9-yl)methoxy)-3-hydroxypropyl (2S)-2-amino-3-methylbutanoate, RefChem:56199, ganciclovir L-valyl ester, Ganciclovir L valyl Ester, DTXCID3028263, J05AB14, L-Valine, 2-((2-amino-3,6-dihydro-6-oxo-9H-purin-9-yl)methoxy)-3-hydroxypropyl ester, Cymeval, L-Valine, ester with ganciclovir, Valganciclovir (INN), 2-((2-amino-6-oxo-3,6-dihydro-9H-purin-9-yl)methoxy)-3-hydroxypropyl L-valinate, [2-[(2-amino-6-oxo-1H-purin-9-yl)methoxy]-3-hydroxypropyl] (2S)-2-amino-3-methylbutanoate, VALGANCICLOVIR [INN], Valganciclovir [INN:BAN], 2-[(2-amino-6-oxo-3,6-dihydro-9H-purin-9-yl)methoxy]-3-hydroxypropyl L-valinate, NCGC00168779-01, UNII-GCU97FKN3R, HSDB 8085, RS 79070, GlyTouCan:G39772PV, VALGANCICLOVIR [MI], RO1079070/194, SCHEMBL28996, SCHEMBL28998, VALGANCICLOVIR [VANDF], GTPL4716, orb1688778, VALGANCICLOVIR [WHO-DD], CHEMBL1201314, SCHEMBL12672612, GLXC-22223, G39772PV, HY-A0032, EBC-26707, AKOS015896083, AKOS015966553, CS-0950, DB01610, NCGC00387997-02, NCGC00387997-04, 5-Amino-3-[1-(hydroxymethyl)-2-(L-valyloxy)ethoxymethyl]-6,7-dihydro-3H-imidazo[4,5-d]pyrimidin-7-one, DA-58945, NS00000462, Ro-1079070/194, D02495, AB01563009_01, EN300-37158611, Q423384, BRD-A50922295-001-01-3, BRD-A50922295-003-01-9, BRD-A50922295-003-05-0, L-VALINE, ESTER WITH 9-((2-HYDROXY-1-(HYDROXYMETHYL)ETHOXY)METHYL)GUANINE, [2-[(2-amino-6-oxo-1H-purin-9-yl)methoxy]-3-hydroxy-propyl] (2S)-2-amino-3-methyl-butanoate
Theoretical properties:
molecular_formula: C14H22N6O5
molecular_weight: 354.36 g/mol
exact_mass: 354.16516782 g/mol
formal_charge: 0
hydrogen_bond_donor_count: 4
hydrogen_bond_acceptor_count: 8
rotatable_bond_count: 9
heavy_atom_count: 25
topological_polar_surface_area: 167 Å²
isotope_atom_count: 0
covalently_bonded_unit_count: 1
Physical properties:
solubility: 4.79e+00 g/L
Descriptions:
pubchem: Valganciclovir is the L-valinyl ester of ganciclovir, into which it is rapidly converted by intestinal and hepatic esterases. It is a synthetic analogue of 2'-deoxyguanosine. It has a role as an antiviral drug and a prodrug. It is a member of purines and a L-valyl ester. It is functionally related to a guanine and a ganciclovir.
chebi: The <small>L</small>-valinyl ester of ganciclovir, into which it is rapidly converted by intestinal and hepatic esterases. It is a synthetic analogue of 2'-deoxyguanosine.
chembl: VALGANCICLOVIR is a small molecule listed in the ChEMBL database and has reached clinical trial phase 4.0.
wikipedia: Valganciclovir, sold under the brand name Valcyte among others, is an antiviral medication used to treat cytomegalovirus (CMV) infection in those with HIV/AIDS or following organ transplant. It is often used long term as it only suppresses rather than cures the infection. Valganciclovir is taken by mouth.
Common side effects include abdominal pain, headaches, trouble sleeping, nausea, fever, and low blood cell counts. Other side effects may include infertility and kidney problems. When used during pregnancy, it causes birth defects in some animals. Valganciclovir is the L-valyl ester of ganciclovir and works when broken down into ganciclovir by the intestine and liver.
Valganciclovir was approved for medical use in 2001. It is on the World Health Organization's List of Essential Medicines. In 2017, a generic version was approved.